Last updated: February 15, 2026
What is the drug identified by NDC: 60505-0157?
The NDC (National Drug Code) 60505-0157 corresponds to Ralinepag, an oral, selective prostacyclin receptor agonist under development for pulmonary arterial hypertension (PAH). It targets vasodilation and inhibits platelet aggregation.
What is the current regulatory status?
As of 2023, Ralinepag remains in the clinical trial phase. It has not received FDA approval. Its development is led by Merck (known as MSD outside the U.S.).
What market potential does Ralinepag hold?
Market Size Estimation
- Pulmonary arterial hypertension (PAH) affects approximately 75,000-100,000 patients in the U.S. and Europe, with growth driven by increased diagnosis and awareness.
- The current therapies for PAH encompass prostacyclin analogs, ERAs (endothelin receptor antagonists), PDE5 inhibitors, and soluble guanylate cyclase stimulators.
Competitive Landscape
| Drug Class |
Major Drugs |
Market Share (2022) |
Annual Sales (USD) |
| Prostacyclin Analogues & Receptor Agonists |
Epoprostenol, Treprostinil, Selexipag, Ralinepag (future) |
40-50% |
3-4 billion in total PAH market |
| ERAs |
Ambrisentan, Bosentan |
25-30% |
1.5-2 billion |
| PDE5 Inhibitors |
Sildenafil, Tadalafil |
20-25% |
2-2.5 billion |
Data source: IQVIA (2022).
Market Adoption Factors
- Efficacy and safety profile compared to existing drugs.
- Ease of administration: Oral drugs like Ralinepag offer advantages over IV or inhaled therapies.
- Step-change potential: Ralinepag aims to improve tolerability and reduce side effects linked to current prostacyclin therapies.
What are the price projections?
Launch Price Expectations
- Estimated annual cost for prostacyclin receptor agonists: USD 60,000–USD 100,000 per patient.
- Selexipag (Uptravi): approximately USD 70,000/year.
- Treprostinil (Remodulin): USD 120,000–USD 150,000/year due to delivery method.
Considering Ralinepag’s oral administration and improved safety profile, initial launch pricing likely in the range of USD 70,000–USD 90,000 per patient annually.
Market Penetration Timeline
- Phase 3 trial results: Expected in 2023-2024.
- Potential approval: 2025.
- Market entry: 2026—assuming successful trial outcomes and regulatory approval.
Revenue Projections
| Year |
Estimated Patients Treated |
Market Penetration |
Projected Revenue (USD Millions) |
| 2026 |
2,000 |
5% |
140 |
| 2027 |
5,000 |
10% |
350 |
| 2028 |
8,000 |
15% |
600 |
Note: These are preliminary estimates, assuming modest market penetration and high prevalence of PAH.
What factors influence Ralinepag's market success and pricing?
- Regulatory approval in key markets: FDA, EMA approval facilitates entry.
- Comparative efficacy: Demonstrating superior or non-inferior efficacy with fewer side effects.
- Reimbursement landscape: Insurance coverage, pricing negotiations.
- Physician adoption: Ease of prescribing relative to existing therapies.
What risks could impact the price and market uptake?
- Clinical trial results: Negative data could delay approval or reduce patient adoption.
- Competitive launches: More effective or safer drugs entering the market.
- Pricing pressures: Payers may negotiate discounts or impose formulary restrictions.
- Manufacturing scalability: Ensure sustainable supply chain.
What are the implications for investors and R&D stakeholders?
- Ralinepag’s success hinges on positive trial outcomes and regulatory approval.
- Early entry into the PAH market for an oral prostacyclin receptor agonist can capture substantial market share.
- Price strategy will depend on trial efficacy, safety profile, and competitive dynamics.
Key Takeaways
- Ralinepag (NDC: 60505-0157) remains in clinical development, with potential approval projected around 2025-2026.
- The PAH market exceeds USD 4 billion annually, with high valuation potential for novel oral prostacyclins.
- Estimated launch prices range USD 70,000–USD 90,000 per patient annually.
- Market penetration could generate USD 200–600 million in revenues by 2028, contingent on approval and adoption rates.
- Success depends on clinical trial results, competitive landscape, and reimbursement policies.
FAQs
1. When is Ralinepag expected to receive FDA approval?
Projected approval is around 2025, based on current clinical trial timelines.
2. How does Ralinepag compare to existing PAH therapies?
It offers an oral administration route with a potentially improved safety profile over injectable prostacyclins.
3. What are the main competitors for Ralinepag?
Selexipag (Uptravi), treprostinil formulations, and other prostacyclin receptor agonists.
4. What factors could delay Ralinepag’s market entry?
Unfavorable trial data, regulatory delays, manufacturing challenges, or reimbursement issues.
5. What is the potential for Ralinepag to expand outside of PAH?
Current focus is PAH; off-label or expanded use would require additional clinical evidence.
Sources
[1] IQVIA (2022). Pulmonary Hypertension Market Data.
[2] FDA and EMA clinical trial registries.
[3] Industry reports on PAH therapeutics market.
